

SRSP1 (N-20): sc-139434

BACKGROUND

SRSP1, also known as SPATS1 (spermatogenesis associated, serine-rich 1) or SPATA8, is a 300 amino acid protein that exists as 2 alternatively spliced isoforms and may play a role in spermatogenesis. The gene encoding SRSP1 maps to human chromosome 6, which contains 170 million base pairs and comprises nearly 6% of the human genome. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer, suggesting the presence of a cancer susceptibility locus. Additionally, porphyria cutanea tarda, Parkinson's disease, Stickler syndrome and a susceptibility to bipolar disorder are all associated with genes that map to chromosome 6.

REFERENCES

- Mungall, A.J., et al. 2003. The DNA sequence and analysis of human chromosome 6. *Nature* 425: 805-811.
- Vuoristo, M.M., et al. 2004. A stop codon mutation in COL11A2 induces exon skipping and leads to non-ocular Stickler syndrome. *Am. J. Med. Genet. A* 130: 160-164.
- McQueen, M.B., et al. 2005. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. *Am. J. Hum. Genet.* 77: 582-595.
- Batts, K.P. 2007. Iron overload syndromes and the liver. *Mod. Pathol.* 20 Suppl. 1: S31-S39.
- Olsson, K.S., et al. 2007. The HLA-A1-B8 haplotype hitchhiking with the hemochromatosis mutation: does it affect the phenotype? *Eur. J. Haematol.* 79: 429-434.
- Park, E., et al. 2007. Modulation of parkin gene expression in noradrenergic neuronal cells. *Int. J. Dev. Neurosci.* 25: 491-497.
- Safadi, S.S., et al. 2007. A disease state mutation unfolds the parkin ubiquitin-like domain. *Biochemistry* 46: 14162-14169.
- Bläker, H., et al. 2008. Recurrent deletions at 6q in early age of onset non-HNPCC- and non-FAP-associated intestinal carcinomas. Evidence for a novel cancer susceptibility locus at 6q14-q22. *Genes Chromosomes Cancer* 47: 159-164.

CHROMOSOMAL LOCATION

Genetic locus: SPATS1 (human) mapping to 6p21.1.

SOURCE

SRSP1 (N-20) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the N-terminus of SRSP1 of human origin.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

PRODUCT

Each vial contains 100 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-139434 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

SRSP1 (N-20) is recommended for detection of SRSP1 of human origin by Western Blotting (starting dilution 1:100, dilution range 1:50-1:500), immunofluorescence (starting dilution 1:25, dilution range 1:25-1:250) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with SPATA10.

Suitable for use as control antibody for SRSP1 siRNA (h): sc-95320, SRSP1 shRNA Plasmid (h): sc-95320-SH and SRSP1 shRNA (h) Lentiviral Particles: sc-95320-V.

Molecular Weight of SRSP1: 34 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.